vimarsana.com

கூட்டுறவு புற்றுநோயியல் குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

COVID-19 Plus Pancreatitis? Think High 30-Day Mortality

P 0.001) P 0.001) P 0.001) The increased mortality, the authors wrote online in Gut, was most likely due to older age, worse performance status scores, and more severe disease and complications in positive patients. In an adjusted analysis, length of hospital stay (OR 1.32, P 0.001), persistent organ failure (OR 2.77, P 0.003), and 30-day mortality (OR 2.41, P 0.04) were significantly higher in co-infected patients. If the infection continues to be prevalent without an effective treatment or vaccine, these data help clinicians to better prognosticate for patients with concomitant AP [acute pancreatitis] and SARS-CoV-2 infection and optimize resource allocation, Nayar and team noted. Emerging data suggest the pancreas is a target organ of SARS-CoV-2 because the angiotensin-converting enzyme receptor is expressed in pancreatic acinar and islet cells.

Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET

Published 12 July 2017 Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET Condition: Prostatic Neoplasms Sponsor: University of Sydney Gender: Male Target or non-target lesions according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 Adequate bone marrow function: Haemoglobin (Hb) ≥100g/L and White Cell Count (WCC) ≥ 4.0 x 109/L and platelets ≥100 x 109/L. Adequate liver function: Alanine transaminase (ALT) Adequate renal function: calculated creatinine clearance > 30 ml/min (Cockcroft-Gault) Eastern Cooperative Oncology Group (ECOG) performance status of 0- Patients with performance status 2 are only eligible if the decline in performance status is due to metastatic prostate cancer.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.